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Abstract
This study  assesses the potential demand by the public  epidemiology  of AIDS  and Brazil's experience  with
sector for a  preventive  HIV/AIDS vaccine  in Brazil and  immunization  coverage with other vaccines are used to
the costs of alternative strategies for a vaccination  assess the number of vaccines,  delivery strategies,  and
program.  Brazil has a mature AIDS epidemic:  the percent  possible costs of an HIV/AIDS immunization  program  in
of the population  living with HIV or AIDS  (about 0.6  Brazil,  assuming the  availability  of a  100 percent
percent of adults)  is not as high as in-other severely  effective  AIDS vaccine  that lasts a lifetime under
affected  developing countries, but infection rates in  different pricing and dosing assumptions.
specific risk groups  in the population are very high  and  A low-cost,  highly effective  vaccine would  likely be
HIV has spread  beyond these groups  into the general  affordable  to an upper-middle-income  country like Brazil
population of low-risk individuals.  and yield large benefits from  a policy of universal,
Preventive  HIV/AIDS  vaccines  are still in the testing  publicly subsidized  immunization. But if prices are higher
stage. The characteristics  of the first vaccines  developed,  and the impact less favorable,  the costs and effects would
in terms of their efficacy,  duration of effectiveness,  ease  have  to be  compared with other AIDS  prevention
of administration,  and price,  are still unknown. But the  programs or other health  interventions.  Both political
potential benefits of such  a vaccine  in Brazil would  be  and economic  considerations will  likely  figure into public
high. The study reviews the cost and impact of HIV/  policy  on HIV/AIDS vaccination,  when such a vaccine  is
AIDS  in Brazil,  in terms of disease and economic burden,  developed.
as a proxy  for the benefits of an HIV/AIDS  vaccine.  The
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The AIDS Vaccine Task Force of The World Bank has commissioned individual case
studies of the potential demand and delivery strategies for an AIDS vaccine in developing
countries, representing both low- and middle-income countries  and different  degrees of
severity of the epidemic,  and Brazil was included in this project.  The objectives  of the study
were to assess the cost and impact of HIV/AIDS  in terms of disease and economic  burden, as
a proxy for the benefits of prevention and of an AIDS vaccine, and the ability to pay of the
public and private sector and individuals, as a proxy for their willingness to pay for an
HIV/AIDS  vaccine.  These estimates and the AIDS vaccine R&D scenario should be the basis
for a discussion about potential costs and benefits of alternative vaccination  strategies and
thus provide inputs for follow-up studies.
Although the availability of this vaccine as a marketing product is still years ahead,
and by that time epidemiologic and social and political conditions may be different in these
countries, this type of study is very useful to increase awareness and preparedness  for when
this happens. The study is based on existing data, research and policy documents,  and the
estimates used have been considered adequate  by the National Aids Program. Vaccination
strategies are referenced by studies developed in other countries, especially Thailand
(Tangcharoensathien  and others 2001), but take into account health and immunization policies
and economic and social conditions  in Brazil.
In this type of study, based on the interpretation of the existing elements to develop
future scenarios, general concepts about health, society and science and technology in and for
health contribute to the analysis on a specific subject, but often are not recognized as
participating elements. We introduce in this first section some of the elements considered
important as a context for our study. In the second section we present a synthesis of
HIV/AIDS epidemiology in Brazil, and in the third a synthesis of health and AIDS
expenditures in Brazil. The fourth section discusses alternative vaccination strategies based on
epidemiological,  economic and health policy estimates and includes the concluding remarks.
The identification and measurement of population health problems and diseases
depends on the articulation of different disciplinary fields, concepts, and data. Among these
fields, epidemiology occupies an important space, through the use of largely accepted and
systematic technical procedures and analytical methodologies.  But it does not in itself define
which will be the health priorities in a given context, for other factors besides epidemiological
magnitude and transcendence contribute to make priorities effectively  so.
The AIDS epidemic worldwide is a clear example.  On the one hand, never before
have so many resources been used for one disease  in such a relatively short time interval, with
impressive scientific results and very positive impacts on the clinical treatment of the disease.
IOn the other hand, the African pandemic and the situation in several other countries, point out
that from a population perspective epidemiological  knowledge alone has not been powerful
enough to guarantee that resources for health care (health care facilities and professionals,
preventive, diagnostic  and therapeutic procedures)  are equitably distributed (Grassly and
others 2001).
It is also significant to observe that the strongest investment, from an industrial point
of view, has been in the development of new drugs, a very successful accomplishment by the
phannaceutical  companies.  Particularly in the last five years, many drugs have been marketed
and combination drug therapies have succeeded in reducing AIDS mortality and HIV
infectiveness and enhancing patient quality of life (Jordan and others 2002). For a decade,
efforts for the development of a vaccine were very limited, and special movements  like the
creation of the International AIDS Vaccine Initiative (IAVI) were necessary to strengthen the
vaccine agenda (Esparza 2001).
This is not very different from what has happened with other diseases. Vaccines have
commonly been slower to develop  and disseminate than drugs, and the involvement of the
public sector is always essential  (IAVI 2001; WHO-UNAIDS 2001; Makgoba,  Solomon,  and
Tucker 2002). To provide access to an AIDS vaccine some commitments have to be made
involving the public sector of rich and poor countries.  As a first step, governments must be
aware of the vital importance of such a vaccine and countries with higher income must
recognize the urgency in controlling the AIDS pandemic and offer financial support. Their
involvement should not be limited to the research and development of an efficient vaccine,
but also with the implementation of an adequate  delivery system. It is clear that in order to
raise the levels of private research and development for an AIDS vaccine a combination of
push strategies, to reduce the cost and scientific risk of investment for the companies,  and pull
strategies, to guarantee  a market, will be necessary (Batson and Ainsworth 2001).
The development of safe and effective vaccines against HIV/AIDS faces several
challenges.  The ideal vaccine  should stimulate the production of antibodies capable  of
neutralizing free viral particles and also the cellular immunity needed to destroy infected
cells. Another challenge is that there is still a lack of understanding of which immune
responses  are necessary to confer protective  immunity.  In other words, there is no knowledge
of the correlates of immunity that would be necessary to evaluate the response to an AIDS
vaccine.  Further complications include the fact that there is not an ideal animal model for
HIV/AIDS. Additional challenges  are that HIV has multiple subtypes and different infection
routes. It is possible that several vaccines (or vaccine "cocktails") will be required to
overcome these challenges.
In spite of the problems, there are some signs of optimism. Trials of vaccines  for
simian immunodeficiency  virus (SIV) on monkeys have provided important information
2about immune mechanisms.  Studies about people who have been exposed to HIV and are
resistant have also contributed to the understanding  on human immunity to HIV. Besides that,
the majority of currently used vaccines have been developed before the precise knowledge on
the immune mechanisms  and correlates were fully understood.
Vaccine research  is a long process that begins with basic science to design
immunogens or vaccine concepts, identification of correlates of immunity, and experimental
trials in animal models. The next step is to translate basic research into candidate vaccines for
evaluation in human volunteers.  Vaccine trials in human volunteers involve three phases.
Phase I and II trials provide data on the safety and immunogenicity of the product. Depending
on the results, the candidate may be moved to Phase III trials, to obtain data on its efficacy.
Since the first human trial of an HIV 1 candidate  vaccine was carried out in the United
States in 1987, a great number of candidate products have been tested.  Several approaches to
the development of an HIV vaccine have been attempted. Initially the majority of the products
focused the virus envelope proteins, which seemed obvious, once the envelope  is the primary
target to neutralizing  antibodies. At least  13 different candidate products targeting gp 120 and
gp 160 envelope proteins have been submitted to Phase  MI/I  trials. They have been shown to
be safe and immunogenic,  having induced neutralizing antibodies in nearly all subjects, but
failed to induce  CD8+ cytotoxic T lymphocytes  (CTL). In spite of the limits posed by low
level neutralizing  antibodies in providing protection from viral infection, one product
developed using this approach has been moved to Phase III trials. The VaxGen bivalent
preparation of gp  120 using one lab isolate (subtype B) and one primary isolate (subtype B or
E) is currently being evaluated in trials in the United States and Thailand. Efficacy results are
not yet available. Besides the recombinant proteins subunits, other approaches  are also being
attempted, such as DNA vaccines, poxvirus vector based vaccines and whole killed virus
vaccines. A candidate product using the canarypox virus vector is currently being evaluated  in
a multicentric trial, which is being carried out also in Brazil (IAVI 2002; NIH 2000; HVTN
2001).
In summary,  these results  so far have shown that: (1)  Several doses of the candidate
products are necessary to induce antibody response; (2) short duration of antibody's titers; (3)
it is not clear whether these products have any effect in stimulating cellular immunity; (4)
antibody response is subtype specific,  and (5)  vaccine trials usually evaluate the candidate
product combined with behavioral risk reduction interventions, whose effectiveness  in HIV
infection risk is variable, depending on the epidemiological  context, making it difficult to
separate the candidate product and the intervention effects;  6) to accelerate the development
of an HIV vaccine, additional candidate vaccines must be evaluated in parallel in both
industrialized and developing countries, and this requires international collaboration and
facing critical ethical considerations  (Esparza and Bhamarapravati  2000; Esparza 2001). At
3this stage, these important scientific uncertainties  contribute to the fact that most
pharmaceutical  companies consider the development of an AIDS vaccine to be risky and
expensive, and no reasonably valid cost estimates are available.
To make this vaccine available for the rest of the world high-income  countries will
have to adopt special price policies and lower-income  countries must be aware of their
responsibility in creating the conditions for an effective and efficient allocation of resources,
while joining the global efforts for the development of a vaccine (Collins and Morin 2001).
Besides epidemiology, diverse conditions of income, educational level, culture and access to
the health system determine the specific strategies that will maximize vaccine  impact.
The social construction of demands in health care are complex processes  involving
scientific knowledge,  health practices, and social, economical and cultural dimensions, as has
progressively been recognized by all those responsible for the definition and implementation
of science and technology (S&T) and health policies. This implies considerable difficulties  in
health impact assessments, for they depend on adequate  definition of possible impacts and
ways of measuring them, on the quality of existing information, on advocacy capabilities  of
those responsible for implementing  the policy under analysis, and on the present and future
economic and political context (Parry and Stevens 2001; Buck, Eastwood,  and Smith  1999;
Bunker 2001; Chapman 2001).
H.  HIV/AIDS Epidemiology  in Brazil
The AIDS epidemic  in Brazil constitutes a very special and vivid example of the
complex articulation between epidemiological knowledge,  public health policies and
economic,  social and political dimensions indicating that the discussion about the potential
impact of an AIDS vaccine needs to take into account an ample range of elements.
Brazil, the largest country in Latin America, had a population of 166 million people in
1998. The working age population (WAP) between  15 and 64 years old,  108 million,
represented  65 percent of the total population. With a relatively recent and intense
urbanization process (81 percent of the population,  ranging from 69 to 90 percent in the
different regions, Census 2000), there is a significant concentration of the population in the
more industrialized areas, the South and Southeast regions of the country.
The Brazilian gross domestic product (GDP) in 1998 was US$ 4,673.69 per capita and
US$ 7,186.51  per WAP, and Table 1 presents the Brazilian  1998 GDP expressed also in
Reais,  the national currency,  and in Purchasing Power Parity and the conversion factors.l
1.  Although American dollars are an international  reference in substitution for local currencies (Real in
Brazil, R$), the purchasing power of American dollars is different in each country and also varies through the
years (Summers  and Heston  1991). Therefore, the GDP per capita of each country is better expressed in
4Poverty did not decline during the nineties, and about 34 percent of the population was
classified as below the poverty level at the end of the decade. Brazil continues to have one of
the most unequal income distributions in the world. The 10 percent of the population with the
highest income controlled  50 percent of the national income, while the 50 percent with the
lowest income controlled only 10 percent of the national income (Brazil 2001).
Table 1. GDP per working age population - Brazil
Current  GDP  GDP  GDP
values  (billion)  per capita  per WAP
R$ (LC)  900  5426.62  8344.25
US$  775  4673.69  7186.51
I$ (PPP)  1145  6907.56  10621.41
Total population  166
WAP - 15 to 64 years old  108
R$ per US$  1.16
R$ per 1$  0.79
R$/l$ per  0.68
Source: World Bank.
According to The World Bank methodology,2 which divides the economies  in four
categories:  low-income,  lower middle-income,  upper middle-income and high-income,  Brazil
is classified as an upper middle-income economy. Other countries also classified as upper
middle-income are Venezuela,  Argentina, South Africa, Turkey and Poland.
One of the most important differences  with other countries in this category is the
educational  level of the population,  which improved in the last decade but is still lower than
could be expected. Although in the year 2000, 95 percent of the children aged 7-14 years were
Purchasing Power Parity (PPP), also known as International  dollars (I$). Table I presents the Brazilian  1998
conversion factors: R$  1.16 per US$, R$ 0.79 per I$ and R$fI$ 0.68 per R$/US$.
The Brazilian  1998 PPP per exchange rate  (R$nI$ 0.68 per R$IUS$)  indicates that, in  1998, US$ 68.00
could buy in Brazil the same basket of goods as US$ 100.00 in the United States. In 1999, however,  due to the
Brazilian Real devaluation, US$ 45.00 was enough to buy in Brazil the same basket of goods as US$  100.00 in
the United States. The Brazilian  1999 conversion factors were R$  1.81 per US$, R$ 0.81 per I$ and R$/I$ 0.45
per R$/US$ (World Bank 2001). Almost all domestic good prices in Brazil (non-tradable  and even exportable
goods) decreased in current US$ from 1998  to 1999 due to the local currency devaluation (from R$  1.16 per US$
in 1998 to R$  1.81 per US$ in 1999). The variation of the Brazilian conversion factors explains why the
Brazilian GDP per WAP decreased in current American  dollars (from US$ 7,186.51  in 1998 to US$ 4,808.82 in
1999) at the same time that increased in current Intemational  dollars (from 1$  10,621.41  in  1998 to I$ 10,773.73
in  1999).
2. For an explanation about this method see:
http://www.worldbank.org/data/databytopic/class.htm#Definitions_of_groups
5attending school, only 78 percent of those aged 15-17 and 31 percent of those aged 18 to 25
did so. Tables 2 and 3 indicate the existing significant regional differences.  Educational level
is considered to be an important element in intervention policies for AIDS, as shown in
preventive behavior and adherence to ARV therapy, and in immunization policies in general.
Table  2. Distribution  of Brazilian adults 15 years and older by the highest level of schooling attained,
by gender and region,  1998  (percent)
Region
Gender and schooling level  North  Northeast  Southeast  South  West  Total
Men  100  100  100  100  100  100
Elementary*  75  83  69  73  74  74
High school  20  13  20  18  18  18
College  5  4  10  8  8  8
Women  100  100  100  100  100  100
Elementary*  71  78  67  71  69  71
High school  24  17  22  20  23  20
College  5  5  11  9  8  9
Source: FIBGE,  2000.
* illiterates included.
Table 3.  Number of high school and college students in Brazil, by gender and region,  1998
(thousands)  Region
North  Northeast  Southeast  South  West  Total
High school  417  1,457  3,595  1135  532  7,136
Men  171  588  1,631  509  219  3,117
Women  247  869  1,965  626  313  4,020
College  87  356  1,281  488  185  2,398
Men  40  138  590  204  77  1,048
Women  48  219  692  284  108  1,350
Source: FIBGE,  2000.
Macro level political will is essential for the development of effective and efficient
HIV/AIDS policies.  The perception by both government  and civil society of the significance
of an even wider AIDS dissemination can contribute to the political basis for an adequate
distribution of resources. Brazil has been internationally recognized for its positive policies in
AIDS treatment and prevention.  Free distribution of AZT started, very slowly, in  1988, with
drugs for treatment of some opportunistic infections. Anti-retroviral  therapy was introduced in
the public health services in 1991.
The strengthening of  the democratic political system in the late eighties and beginning
of the nineties made it possible for society to express a growing demand for political actions
6concerning AIDS. In response to these social demands in 1990 a STI/AIDS National Program
was created in the Ministry of Health,  in order to centralize  the decisions and policies
involving AIDS prevention and treatment. This National Program was, and still is, financially
supported not only by the Brazilian government, but by loans from international
organizations,  like the World Bank and Panamerican  Health Organization.
In 1996, with the promulgation of a Federal Law3 the Brazilian government decided to
supply all AIDS cases with the necessary treatment drugs, based on a medical consensus,  and
the budget expenses related to AIDS started to increase considerably.  Just the expenditures  for
anti-retroviral  drugs grew approximately  17 times (Brazil  1999b) between  1996 and 1999.
Brazil is considered to have reasonable  to good quality health information,  but of
irregular distribution, with some regions still with very deficient health information systems,
but existing information is easily accessible through several official databanks. The mortality
information system has an increasing reliability and credibility and nowadays information
from the state capitals, with a big share of the population, have an adequate standard,
especially in the South and Southeast regions.
Hospital morbidity information is provided by the Autorizac6es  de Internacao
Hospitalar information system which registers all hospitalizations  financed by the public
health care system, the Sistema Unico de Sauide (SUS). Although essentially of an
administrative and financial nature,  it provides useful information  about government funded
hospitalizations  and since most AIDS cases are treated in SUS hospitals, it constitutes  a good
information source for this study.
The information  concerning the mandatory notification list of diseases  is registered  in
the Sistema de Informacao de Agravos de Notificacao (SINAN),  and includes AIDS. This
information  system is coordinated by the epidemiological  surveillance system and can be
considered a reasonably consolidated system, allowing the follow up of these diseases on a
national  level. One of the problems, and this affects AIDS notification very much, is the time
it takes the local and regional authorities to clear the technical  elements involved with correct
notification, before registering the information  in the SINAN.  Although statistical methods
have been developed to minimize this underestimation of recent numbers, data are more
precise with two to three year interval (Luiz and Costa 2001), which is the reason why in this
study we will be using 1998  as our year of reference. Data for more recent years seem to
indicate a tendency for a decrease in AIDS incidence, but in this study it seems preferable to
incur in overestimation rather than underestimation  of the number of cases.
3.  Lawn° 9313,  13/11/1996.
7Besides these national health information systems, there are other systems,  at both the
federal and state levels, that give access to social and demographic  information obtained in
the Census and several other official surveys, which enable the identification of the social,
political and economic  situation of the Brazilian population.
The scientific community in Brazil has increased its volume of research and
publications in the last decade, and in the health area particularly  so. Epidemiological and
public health investigations frequently articulate the universities with the public health sector,
and the Ministry of Health and State Secretaries of Health contribute  with the dissemination
of these studies through their websites. The National AIDS Program has been especially
active in the dissemination of research results concerning HIV/AIDS and sexually transmitted
infections  (STI).
Brazil's population health situation shows as its first cause of death the circulatory
diseases (158/100,000), with cancer and external causes in second (68/100,000  and
72/100,000, respectively).  Deaths from infectious diseases, dominated  by diarrhea,  which
went down significantly in the 1970s and 1980s with the improvement of sanitary conditions,
have now TB and AIDS as important causes. The specific death rate for AIDS was
6.65/100,000 in 1998 (IDB 2001: www.saude.gov.br).
In the period between  1987 and 1996 the pattern of AIDS changed from one
concentrated in specific regions and social groups to a national scale affecting all social
groups (Szwarcwald  and others 2000a).  In recent years the dissemination apparently slowed
down, which may possibly be explained by the "exhaustion"  of susceptibles, changes in
population behavior and the introduction of ARV therapy on a large scale (PAHO 2001). This
was partly due also to the widely disseminated  official educational and preventive measures,
through its coordinating centers, and the activities of non-governmental  organizations, present
all over the country, and with high capacity of action and intervention. Nevertheless,  an
important concentration of number of cases continues to be observed in the States of Sao
Paulo and Rio de Janeiro,  in the more developed  Southeast region.
Recent publications point out a tendency of stabilization of the disease. While, in
1991, incidence was circa 8 cases for 100,000 inhabitants,  it rose to 13,7 cases for I05 in 1998
and fell to 11,2 for  105 in 1999 (Teixeira and others 2001). Table 4 shows the number of
notified AIDS cases for the period between 1995-1998 for Brazil and its regions. There is a
continuous growth of notifications  in the period of 1995-1998,  except for the southeast
region, where in 1997 a declining tendency is already clear, and the west region, where new
cases declined in 1998.
8Table 4. Newly reported AIDS cases by year and region, Brazil 1995-1998
Region  1995  1996  1997  1998
North  362  435  501  519
Northeast  1,596  1,984  2,224  2,628
West  1,184  1,260  1,430  1,195
Southeast  14,112  15,618  15,251  14,572
South  3,103  3,646  4,139  5,101
Brazil  20,357  22,943  23,545  24,015
Source:  Boletim Epidemiol6gico Aids 14(2), 2001.
Besides the dissemination on a national scale, AIDS cases changed their social-
economic profile. While first affecting predominantly  individuals from the middle and upper
classes, in the  1990s the epidemic went through what has been called a pauperization process
(Szwarcwald and others 2000b; Fonseca and others 2000; Parker and Camargo 2000) This has
been partially explained by the increase of cases among intravenous drug users (IDU), by
changes in the exposition and transmission categories and the substantial variation in
knowledge about HIV infection according to educational level (Medeiros, Barbosa, and
Aguiar 2001).
As for the exposure categories, described initially among men who have sex with men,
and hemophiliacs,  later on they expanded to other groups like IDU, and finally to
heterosexuals, with a very important increase among women, and some other categories, like
the so-called marginal or "forgotten" groups, prisoners, homeless, and ethnic minorities,
among others. Heterosexual transmission in 1998 occurred in 42 percent of the cases, men
who have sex with men (MSM) in 19 percent and IDU in  16 percent (3 percent perinatal,  20
percent unknown).
An estimated  155,590 AIDS cases had been diagnosed by the end of 1998, with about
50 percent still alive and about 80 percent of these were under treatment. New cases continue
to be included.  In recent years methodologies using sentinel surveillance have been
introduced and the estimates of HIV infection prevalence have become more reliable. Adult
(15-49) prevalence rates for 1999/2000 range from 0.57 percent  (UNAIDS) to 0.65 percent
(AIDS/STD NC/Ministry of Health), with men at 0.84 percent and women at 0.47 percent,
with an estimated 550,000 infected adults alive at the end of 1999 (UNAIDS). HIV
seroprevalence  among antenatal attendees in  1998, part of the sentinel surveillance program,
was less than 1 percent in five sites outside of the major urban sites and data for the regions
range from 0.189 percent (North) and 0.149 percent (Northeast), to 0.555 percent for the
South and Southeast regions (Szwarcwald and Castilho 2002).
9In 1998 pregnancies an estimated  14,222 were HIV positive, with  1,943 infected
newborns, indicating a transmission rate of 14 percent. In  18 percent of the infected
pregnancies  adequate therapeutic  interventions occurred in 1998, and this number is estimated
to have been 30 percent in 2000 (Szwarcwald,  Barbosa,  and Fonseca 2001).
The impact caused by the introduction of therapeutic measures,  like the antiretrovirals
in their different compositions and associations and/or health promotion and protection
measures, though evident, has not been completely explored yet. Data published by Teixeira
and others (2001) show that "the decline of AIDS-related deaths since  1995 coincides with
the adoption of antiretroviral therapies and the free disposition of treatment for all AIDS
cases". While in 1994-95 there was a  13.0 percent increase of deaths,  between  1996-99 a
decline of 31.5 percent has been observed. Impact on life expectancy,  although estimated by
international agencies  at a 5.3 years loss in the years before treatment, were considered to be
much less in a recent national study, and were estimated at 0.3 for Brazil,  with a maximum of
0.7 to 0.8 for Rio de Janeiro and Sao Paulo (Gotlieb, Castilho, and Buchalla 2000).
Temporal trends in AIDS-associated opportunistic infections also indicate a
significant decrease since 1995,  including TB, especially  for the higher educational level
groups (Guimaraes 2000). These data indicate an effectiveness  of antiretroviral therapies, with
an estimated 80 percent level of adherence to treatment in the State of Sao Paulo, probably the
highest level in the country (Nemes 2000).
These results must be associated with prevention and promotion measures,  like
condom distribution program, educational programs and syringe distribution and exchange
but the precise weight of each element for different social contexts still remains unknown.
The long average incubation period between HIV infection and clinical AIDS disease
constitutes  an additional element in making impact analysis more difficult.
As for preventive behavior,  the percentage of condom users in the first sexual
intercourse increased  12 times between  1986 and 1999 (form 4 to 48 percent).  Regular
condom use among sexually active individuals increased  substantially,  in particular among
the younger ages, and this has been a consistent finding in several different studies. Some
recent studies seem to indicate that this relatively high condom use persists even with
decreasing knowledge  about the disease (Szwarcwald  and others 2002).
Although incomplete, the existing numbers for the public and private distribution of
condoms also indicate a growing utilization (UNAIDS 2002). Approximately  200 million
male condoms were purchased in the year 2000 in order to supply projects, campaigns and
public health services,  and recently 2 million female condoms were made available for use in
specific activities (Teixeira and others 2001).
10Non-governmental organizations promoted contact with 31,000 intravenous drugs
users between 1999-2000, organizing the exchange of more than 1,500,000 syringes. Despite
the efforts of the National AIDS Program and NGOs, population coverage of IDU targeted
interventions remains low (around 5 percent). A sharp decline in HIV prevalence has been
observed in some major Brazilian cities in recent years among drug users, due to the
increasing use of crack (Bastos, Telles,  and Hacker 2001).
Brazil's efforts in implementing its priorities for HIV/AIDS control have been
considered as very positive, although more successful in some areas than in others, but they
have depended also, as all other health policies, on the availability of public resources,  and
even with an increasing fiscal burden, these have not been stable in the last decade
(Ainsworth and Teokul 2000; Nandy and Scott 2000; Reis, Ribeiro, and Piola 2001).
m.  Health and AIDS expenditures
Aids cases, income and  private health expenditures
The 1988 Brazilian Constitution guarantees universal public health care for the
population but the implementation of the public Sistema Unico de Sauide  (SUS) in the 1990s
also allowed market segmentation and an expansion of private insurance  coverage among
wealthy people (Almeida 1998). Only 7 percent of the families with the lowest income per
capita (Group  1) had private health insurance, and the coverage grows to 31.2 percent for
Group 2, 63.1 percent for Group 3 and 83.2 percent for Group 4, with the highest income per
capita (Table 5). Poor people in Brazil represent the largest part of the population and 76
percent of the Brazilian population does not have private health insurance coverage.
In 1998,  53 percent of the Brazilian population received up to the equivalent of the
monthly minimum wage per capita (Group 1, Table 5). The annual family income for this
group was I$ 972.97 per capita and their family private health expenditure was only I$ 81.46
per capita/year.  For people in households earning nine or more times the minimum wages per
capita (Group 4), the annual family income was I$ 32,953.92 per capita and their family
private health expenditure was I$ 2,021.28 per capita/year.
11Table 5. Income  distribution and family private health expenditures in Brazil,  1998
Groups  of family income  per capita
Group  I  Group 2  Group 3  Group 4  Total
until 1mw*  +1 to 3mw*  +3 to  9mw*  +9mw*
Population  (%)  53  32  13  3  100
Income (%)  13  28  32  27  100
(Current  I$)
Annual income  per capita  972.97  3,426.60  9,659.25  32,953.92  3,858.1f
Annual expenditures per capita  81.46  287.40  778.94  2021.28  296.12
Health insurance  7.23  73.11  325.06  937.81  97.67
Physicians  3.96  11.91  27.34  75.40  11.69
Other health  professionals  0.31  1.74  5.16  34.74  2.46
Medical exams  2.67  7.88  12.79  34.98  6.62
Drugs  52.63  131.84  232.79  415.62  111.95
Orthopedic/medical  durables  0.11  0.89  2.72  7.66  0.92
Vision products  2.97  12.50  32.38  81.52  12.19
Dental services  5.38  31.39  100.17  309.56  35.21
Hospital care  3.54  10.90  24.53  87.00  11.16
Nursing home  care  0.47  0.90  5.58  11.42  1.60
Others  2.19  4.34  10.43  25.56  4.65
% of population with private  health insurance  7  31  63  83  24
Source:  Kilsztajn, Camara,  and Carmo, 2001.
*mw  = monthly minimum  wage per capita (R  $130.00  or US $ 112.02 or 1  $ 164.56).
Brazil's statistical  system collects the highest level of completed schooling of reported
AIDS cases and this information can be used as a proxy for income (Ramos and Vieira  1996).
The variation in the proportion of cases and the incident AIDS cases in all regions of the
country for both genders indicate that the AIDS epidemic in Brazil started among social
groups with a high education level and progressively disseminated to social groups with lower
education levels (Bastos and Szwarcwald 2000).
Brazil registered 23,632 new AIDS cases in 1998  and 97 percent were  15 years or
older.  The school degree structure of AIDS cases (recorded for 81 percent of the new cases in
1998)  is very similar to the total adult population of Brazil in 1998  (Table 6).
Table 6.  Completed schooling of new AIDS cases compared with that of the adult
population*  in Brazil,  1998 (percent)
Elementary**  High school  College  Total
New AIDS cases  74  18  8  100
Total Brazilian  population  73  19  8  100
Source: Brazil. Ministry of Health, 2001 b (AIDS);  FIBGE, 2000 (population).
*0 to 14 years old excluded; **illiterate  included.
Considering the similarity of the schooling of adult AIDS cases with the Brazilian
population  and the correlation of schooling with income,  family income and private health
expenditures data from the  1998 Brazilian Household  Sample Survey (FIBGE 2000)  can be
used to infer other characteristics  of AIDS patients.
12AIDS expenditures and economic loss
The introduction of highly active antiretroviral therapy (HAART) in 1996 decreased
the frequency of opportunistic  infections (01) and prolonged life in AIDS patients, reducing
social security  costs in Brazil (Brazil  1999b).  Expenditures with antiretroviral drugs (ARV),
I$ 382 million in  1998, represented  53 percent of the total public AIDS expenditures  in Brazil
(I$ 727 million in 1998). Other public treatment expenditures, including 01 drugs, laboratory
tests for management of HIV infection and hospitalization, represented I$ 127 million. Blood
screening, laboratory  tests for diagnosis of HIV infection, condoms and other preventive
public expenditures were responsible  for I$  157 million. Public expenditures (federal,  85
percent, state and municipal,  15 percent)  for AIDS represented around 3 percent of the
Ministry of Health budget in 1998 (around I$ 24 billion).
Private AIDS expenditures in 1998 were estimated  in I$ 234 million, 63 percent for
condoms. There is no available  information about how much is spent on blood screening in
the private sector, and no amount could be introduced in Table 6, but it may not be negligible,
especially in those regions (South and Southeast) where the private health care system is
stronger (covering up to 50 percent of the population, but leaving ARV treatment and other
costly procedures - transplants,  hemodialysis, etc., for the public sector).
National public and private AIDS expenditures  reached I$ 961  million in 1998 (Table
7), and were 28 percent higher than in 1997, even with a 1 percent budget reduction in the
Ministry of Health. In recent years Brazil has been able to pay less than other countries for
ARV drugs and is producing quite a few of them as generics, but new drugs are continuously
being discovered and introduced in the therapeutic consensus.  On the other hand, less is being
spent on hospitalizations  and OI treatment,  and officials of the AIDS Program consider ARV
treatment already cost-effective.
Nevertheless,  the socioeconomic impact of the epidemic  is very important.
Considering  that in 1998: (a) 95 percent of AIDS deaths occurred in the working age
population (10,204  deaths); (b) the average age of those deaths was 36 years; and (c)  the GDP
per WAP was I$  10,621.41  - the total GDP loss to the country on account of AIDS premature
death in 1998 was I$ 3,035 million. This concept takes into account that the economic loss
from AIDS deaths in a specific year will be distributed over 28 years (36-64) but the GDP of
that year is already affected by AIDS deaths from previous years. Medici  (1994), applying an
alternative method, estimated the Brazilian annual economic  loss in US$ 2,700 million.
13Table 7.  AIDS expenditures  and economic loss due to AIDS in Brazil,  1998
(Current values)
AIDS expenditures  Public  Private  Total
(1$ million)  (/)  (1$ million)  (/)  (I$  million)  (%)
Prevention  157  22  198  84  355  37
Blood  screening  37  5  - - 37  4
HIV tests  88  12  - - 88  9
Condoms  7  1  147  63  154  16
Other  25  4  51  22  76  8
Treatment  509  70  36  16  545  57
ARV  382  53  - - 382  40
Other  127  17  36  16  163  17
Institutional  development  61  8  - - 61  6
Total  727  100  234  100  [a] 961  100
AIDS economic loss
AIDS deaths - 1998  10767 deaths
AIDS deaths 15 to 64 years old - 1998 [b]  10204 deaths
Average age of AIDS deaths  36 years old
Average years to 64 per person  [c]  28 years
GDP per WAP  (1$)  [d]  10621.41
Economic  loss per year (I$ million)  [e=b.c.d]  3035
AIDS expenditures and economic loss (I$ million) [a+e]  3996
per capita  (1$)  24.10
% of GDP  0.35
Source: Brazil.  Ministry of Health, 2000 (expenditures),  2001a (AIDS deaths);
2001 e (distribution  of laboratory tests between  prevention and treatment);  Table 1.
Together, AIDS expenditures (public and private) in 1998 and economic  loss due to
AIDS deaths in 1998 were responsible for I$ 3,996 million (I$ 24.10 per capita, 0.35 percent
of the 1998 Brazilian GDP). Besides AIDS expenditures and economic loss, AIDS morbidity
and mortality increase the social security costs and also cause other serious economic impacts,
tangible and intangible,  to family members. Increased life expectancy and less morbidity in
treated AIDS patients may have an impact on these estimates in the next years, but are
presently difficult to measure.
AIDS cost  per  patient/year
International AIDS cost comparison is very problematic  due to differences  in data
quality, clinical records, responses to treatment, disease severity, use of public versus private
services etc (Cameron  1992). It is also very difficult to compare AIDS cost per patient in
14different countries and years without a purchasing power parity strictly designed for AIDS
cost comparison (that takes into account the structure and prices of AIDS cost in different
countries and time).
In many countries the same ARV drug and other AIDS related goods prices differ in
American dollars as well as in International  dollars. Also, the price of a specific drug can be
reduced and new drugs introduced, and the total cost per patient can vary in different
proportions or even directions  in terms of local currency, American dollars or International
dollars: ARV therapy in a particular country can decrease in constant US$ while increasing in
constant local currency (and the Ministry of Health budget is always enacted in local
currency).
The first cost estimate for treating AIDS in Brazil was US$  16,689.00 per patient in
1989 (Medici  and Beltrao  1992). For 1996, AIDS cost was estimated in US$ 5,597.49 per
patient/year:  US$ 2,786.71  for services and drugs (direct costs) and US$ 2,810.78  related to
the AIDS share of general hospital costs (FIPE  1998).
In 1998, there were 73,580 reported patients living with AIDS and 55,600 patients on
ARV therapy (Table 8). The Brazilian public health system registered 34,940 AIDS
hospitalizations  in 1998, with an average of 18 days per hospitalization  (Brazil 2001d), and
very few AIDS patients are hospitalized outside the public health system.
Table 8.  AIDS treatment  expenditures per patient/year,  Brazil, 1998
(Current l$)
ARV  01 drugs  Laboratory  Hospital  Other  Total
tests
Total (million)  382  35  9  34  85  545
(%)  70  6  2  6  16  100
Per patient living with AIDS
(average:  73,580 patients)  5,195.64  475.82  122.27  460.55  1,159.28  7,413.54
Per patient on ARV therapy
(average:  55,600 patients)  6,875.81  629.69  161.80  609.48  1,534.16  9,810.95
Source: Brazil. Ministry of Health, 2000 (expenditures),  2001 b (AIDS patients),
2001c (on ARV therapy).
According to Table 8, the total public and private AIDS expenditures with treatment
was I$ 545 million in 1998. ARV therapy corresponds to 70 percent of the total expenditures
with treatment,  I$ 5,195.64 per patient living with AIDS and I$ 6,875.81 per patient on ARV
therapy. The estimate per patient on ARV therapy is consistent with the recent National AIDS
Drug Policy value, US$ 4,860.00 (I$ 7,139.38) in 1998  (Brazil 2001c).
1501 drugs, laboratory tests for management of HIV infection, hospital and other
treatments in  1998 were estimated, respectively,  in I$ 629.69, I$ 161.80, I$ 609.48 and I$
1,534.16 per patient on ARV therapy. Total AIDS treatment expenditures in 1998 were I$
7,413.54 per patient living with AIDS and I$ 9,810.95  per patient on ARV therapy.
Good quality cost-effectiveness  studies of HIV/AIDS  interventions are rare in Brazil
(as in most developing countries)  (Creese and others 2002) and there are no available data to
be used in this study.
IV.  Vaccination  strategies for an HIV/AIDS  vaccine
To develop vaccination strategy scenarios,  information about HIV prevalence  and
incidence  in the adult population and for specific high risk social  groups, the utilization of
preventive measures (condom use in particular)  for these same groups,  STI prevalence and
estimates of infectivity in treated AIDS patients constitute the nuclear epidemiologic
information (Barbosa and Struchiner 2002). With the utilization of mathematical models,
these data, together with estimates of vaccine effectiveness,  have shown that high-efficacy
vaccines manage to impact on HIV prevalence, in spite increased risk behavior, but that trade-
offs increasingly get worse the more imperfect the vaccine (Massad 2001).
A recent World Bank paper,  with data from Zimbabwe, Uganda and Thailand and
computer simulation models, investigated the epidemiological  impact of an HIV/AIDS
vaccine, and indicated that even with a vaccine effectiveness  as low as 50 percent it could be
useful in controlling the epidemic, with high coverage  (65 percent or more of the adults). If
efforts to maintain safe sex behavior are not successful, behavioral reversals could eliminate
most of the benefits of the vaccine.  Vaccination programs targeted to high-risk groups would
forcefully have better cost-effectiveness  than vaccinating all adults, but total impact might be
less and politically difficult to justify in countries with generalized epidemics  (Stover and
others 2002).
Immunization policies in Brazil  and an HIV/AIDS vaccine: The National  Immunization
Program
The Brazilian version of the Expanded Program of Immunization, named Programa
Nacional de Imunizac6es  (PNI), was established in 1973. It gained public visibility with the
poliomyelitis  eradication campaigns, which began in 1980. Poliomyelitis  transmission was
interrupted in Brazil in 1989.  Since then PNI has expanded  itself, in the numbers of vaccine
delivery sites, doses delivered, as well as with the incorporation of new vaccines targeted  at
different population groups.
Routine childhood vaccines  include OPV, DTP, BCG, HIB, MMR and hepatitis  B.
Vaccine  coverage for routine vaccines increased to more than 90 percent among one-year-old
16children in recent years. Vaccine preventable disease incidence has decreased to record low
levels among young children.
The vaccine delivery system includes more than 26,000 vaccination  delivery sites
(capable of administering  all official vaccines) and a well established refrigeration network,
with a national storage and distribution center located in Rio de Janeiro and 27 state centers,
in each of Brazil's  states. Vaccines  are purchased centrally by the Ministry of Health and
distributed to states and local health departments.  In 2000, the budget for vaccine purchase
was I$ 296 million. In the same year  179 million vaccine doses were delivered.
Several initiatives are currently being undertaken to expand PNI beyond childhood
vaccines. Yellow fever vaccination has been intensified especially in sylvatic yellow fever
endemic areas, such as the Amazon region and Central-Western  Brazil. More than 40 million
people above 1 year of age were vaccinated since  1998. Since  1999 the country has begun
national annual campaigns of influenza vaccination, targeting the over-60 age group, and the
goal of vaccinating 70 percent of that age group was accomplished in 2000 and 2001. A
national  campaign to reduce the incidence of congenital rubella was also undertaken in 2001;
its goal was to vaccinate  95 percent of non-pregnant  women from 12 to 29 years of age.
Preliminary figures point to a coverage of 92.7 percent, for a population of 15.3 million
women.  Although short of the goal, the numbers show the capacity of the PNI in mobilizing
resources to vaccinate more than  14 million adults in one month. Vaccines are also
administered in private clinics, and although there are no good numbers to estimate their
participation in the national immunization coverage, it is considered to be small and restricted
to larger cities.
Brazil also has three large vaccine research and development institutes and production
plants, Instituto Butantan, in Sao Paulo, FIOCRUZ,  in Rio de Janeiro, and TECPAR, in
Curitiba. Their production accounts for a large share of the country's vaccines'  needs. In
2001, their production reached  193 million vaccine doses. They are modernizing their
facilities and are also participating with foreign pharmaceutical  industries in programs of
technological  transfer for the production of newly introduced vaccines, such as HIB and
influenza (Brazil 2002).
Epidemiological  and  policy estimates  for potential  target groups
The estimates by this study of the size of potential target groups for HIV/AIDS
vaccination in Brazil by relative riskiness of behavior and accessibility (Table 9), are based
on several large studies supported by the National AIDS Program. They can be found at the
site www.aids.gov.br/final/biblioteca  and are referred at the end of the text.  References  and
explanations of the calculations  are in Annexes  1  a and lb.
17Table 9. ClassIfication of potential target groups for vaccinaUon by relative riskiness of behavior and ease of access
Group  HIV  Behavior  linfections prevented  Relatve  How group
(and partners)  prevalence  Partners  Condom  With con-  Without  access  reached
a  b  c  doms d^  e=(ab)+a
1 Sex workers  0.1300  2401.00  31.434  312.260  low  health services
(customer)  2400.00  0.90  NGO
(regular sex)  1.00  0.20  associations
2  IDU  0.1500  64.00  7.890  9.750  low  health services
(needle share)  42.00  NGO
(casual sex)  20.00  0.60
(regular sex)  2.00  0.20
3 Pfsoners  0.1500  13.30  1.575  2.145  high  prisons
(needle share)  6.30
(casual sex)  6.00  0.60
(regular sex)  1.00  0.20
4 MSM  0.1000  126.00  1.540  12.700  low  health services
(casual sex)  120.00  0.90  NGO
(regular sex)  6.00  0.60
5  STI: men  0.0465  61.00  1.195  2.883  low  health services
(casual sex)  60.00  0.60
(regular sex)  1.00  0.30
6  Transport workers  0.0130  21.40  0.116  0.291  medium  assocations
(casual sex)  20.00  0.66  road facilDties
(regular sex)  1.40  0.20
7 STI: women  0.0225  3.00  0.056  0.090  low  health services
(casual sex)  2.00  0.60
(regular sex)  1.00  0.30
8  Military  0.0084  2.77  0.34  0.024  0.032  high  armny facilities
9  Police  0.0084  1.49  0.34  0.017  0.021  high  police facilities
10  Health workers  0.0065  1.30  0.35  0.012  0.015  high  health services
11  Pregnant women  0.0047  1.22  0.35  0.008  0.010  high  health services
12  HS and univ.students  0.0013  3.00  0.48  0.003  0.005  high  schools
13 Conscripts  0.0013  2.77  0.48  0.003  0.005  high  army facilites
I  Men:  15-49  0.0084  1.49  0.34  0.017  0.021  medium  heafth services
2  Women:  15-49  0.0047  1.22  0.35  0.008  0.010  medium  health services
Source: See table 12.
*  d=(ab,(1-c,))+a, where  i is the group or sub-group (e.g., client of sex workers).
HIV prevalence data for specific population groups, such as MSM, IDU, prisoners,
commercial  sex workers and transport workers were estimated from several surveys and
epidemiological  studies.  The HIV national sentinel survey network routinely collects
prevalence data in specific groups (pregnant women, military conscripts, newborns and STI
patients). Sentinel surveillance data for pregnant women and conscripts have been used by the
National STI/AIDS Program to estimate  HIV prevalence  in the general population. In the
present study these data were used as prevalence estimates for the military, police and health
workers, once it was assumed that in the Brazilian  context these groups are not exposed to
different risks than the general adult population. Data on specific risk behaviors were also
collected from published surveys, from estimates of the National  STI/AIDS Program, and by
direct information  formn professionals working on STI/AIDS prevention  initiatives aimed at
specific groups.
18The potential target groups included in Table 9 can be grouped in three categories:
those at high risk, due to relative riskiness of behavior, and low accessibility  (1-7);  those with
high accessibility,  due to institutional access, and at medium to lower risk (8-13); and the
sexually active population (15-49), with a potential although lower risk for HIV/AIDS,  and
medium accessibility.  These groups are plotted according to their ease of access and the
number of infections averted by an AIDS vaccine in Figure 1.
The number of infections caused by each member of these groups (for as long as they
belong to them), assuming no change in condom utilization, that would be prevented with a
100 percent effective vaccine (100 percent efficacy and coverage),  go from a maximum of 31
for sex workers to 0.003 for conscripts.  If vaccine recipients discontinue condom use, then the
number of infections prevented by a vaccine would be even higher.
Figure  1.  Relative accessibility and infection averted with condom,
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Source: Table 9.
Relative accessibility, to the potential target groups was classified in three large
categories, high, medium and low. Sex workers,  IDU, MSM and STI men and women were
considered to be of low accessibility.  These assumptions were based on existing information
in the National AIDS Program and personal communications  of professionals  working with
these groups. As indicated before in this text, population coverage of IDU targeted
interventions  is low. Although there is over-the-counter syringe availability  in pharmacies,
they are too expensive for most IDUs, and pharmacies (to be found in expanding numbers in
most cities) are not allowed to sell vaccines by the health authorities.
19We considered MSM of low accessibility  for although a considerable number
participate actively in NGOs with strong media and political presence,  this is true only in the
bigger cities in the Southeast and South. In other regions of the country homosexuality and
bisexuality is still stigmatized and strategies that imply exposure would be difficult to
implement.
STI patients were considered of low access because a large number of them are poor
and cared for in the public health system. The public sector STI treatment is known to be
relatively ineffective and has low coverage of poor adults. In these low accessibility  groups
some double counting certainly  occurs, but this has not been contemplated in our calculations.
Immunization policies depend almost exclusively on the public sector and
immunization sites are almost always based in community health  services. Routine
immunization (on a daily basis) is practiced almost exclusively in these health services.  Mass
campaigns include some other sites, but they distinguish themselves mainly by happening on
special "national vaccination days", always Saturdays.  The other sites mentioned as places
where specific groups can be reached are self-evident.
Table 10 shows the number of vaccinations required for "catch up" and
"maintenance" vaccination for the potential target groups. "Catch up" means the total
population in each group at the time the vaccine  is first introduced, and "maintenance"  is the
number of new individuals estimated to be added annually in each group. Maintenance
estimates vary according to "tumover"  characteristics in each group. For example,  we
considered pregnant women as having a 100 percent maintenance  size (in relation to catch
up), which implies considering that each year all pregnancies  are first-pregnancies.  This is of
course not true but plausible enough to be used in this scenario, when we take into
consideration the fast lowering Brazilian mean fertility rate. We also assume that men and
women with STIs have a 100 percent maintenance  size in relation to catch-up.4 We estimated
3 million new students joining each year high school and university, in accordance with
existing data. After some years of immunization this number should be smaller, as all students
entering university would have already been vaccinated.
4 The number of male and female STI clients are the number officially reported.  However, as STIs are not
subject to mandatory reporting in Brazil, these are likely underestimates.  There is very little information on
which to base assumptions on the size of  the 'maintenance'  group of STI patients relative to 'catch-up'  size for a
potential AIDS vaccine,  and the estimates below on the costs of altemative strategies are quite sensitive to these
assumptions. Better estimates of the extent of repeat STI clients would improve the reliability of estimates of  the
costs of alternative vaccination strategies.
20Table  10. Size of population groups for catch-up and maintenance vaccination programs and HIV
incidence
Group  Size of the group (thousand)  HIV
Catch up  Maintenance  (b/a)  incidence
a  b  (%)
1 Sex workers  354  6  1.7  0.01000
2 IDU  800  13  1.6  0.01000
3 Prisoners  234  20  8.5  0.01000
4  MSM  3040  50  1.6  0.00500
5 STI: men  3930  3930  100.0
6 Transport workers  700  35  5.0  0.00025
7 STI: women  4800  4800  100.0
8 Military  150  6  4.0  0.00025
9 Police  473  30  6.3  0.00025
10 Health workers  600  27  4.5  0.00019
11  Pregnant women  3500  3500  100.0  0.00017
12 HS and univ.students  9543  3000  31.4  0.00025
13 Conscripts  800  800  100.0  0.00025
1 Men:  15-49  45534  1750  3.8  0.00025
2 Women:  15-49  46955  1750  3.7  0.00017
Source: See table 12.
Incidence estimates were obtained from existing research in specific  and smaller
contexts and expanded to the population group as a whole (Bastos, Telles, and Hacker 2001;
Medeiros, Barbosa, and Aguiar 2001; Szwarcwald and others  1998 and 2000).
Table 11 presents the budget requirements in international  dollars (I $) for two
vaccines,  one costing closer to what most vaccines cost today (I $1), and the other with a
maximum affordable price for governments  (I $10), even in developed  countries (Bishai, Lin,
and Kiyonga 2000). We introduced  in our estimates a delivery cost ranging from 0.20 to 0.40
of the vaccine cost taking into account the increase  in delivery cost with lower accessibility.
These price estimates,  and the decision to consider the number of doses to be bought
as at least equal to the size of the population are conservative.  Depending on the technical
characteristics of the vaccine and campaign strategy, quite frequently immunization officials
buy up to 20 percent more doses than the population size, even when desired coverage is 90
percent.
When comparing costs for different groups it is important to consider both catch up
and maintenance costs, for some groups are smaller but have high maintenance numbers (STI,
pregnant women) and others are large but have low maintenance numbers (men and women
15-49), and total costs after some years are a better measure for comparison.
21Table  11.  Budget requirement in $1
Group  Delivery  Catch-up ($1  1000.00)  Annual maintenance ($1  1000  00)
cost per  Vaccine: $1 1.00  Vaccine: $1 10.00  accne  $11.00  Vaccine:  $1  10.00
dose  1 dose  2 doses  1 dose  2 doses  1 dose  2 doses  1 dose  2 doses
1 Sex workers  0.40  496  991  3682  7363  8  17  62  125
2  IDU  0.40  1120  2240  8320  16640  18  36  135  270
3  Prisoners  0.20  281  562  2387  4774  24  48  204  408
4  MSM  0.40  4256  8512  31616  63232  70  140  520  1040
5  STI: men  0.40  5502  11004  40872  81744  5502  11004  40872  81744
6 Transport workers  0.30  910  1820  7210  14420  46  91  361  721
Total: 6 groups  12564  25129  94086  188173  5668  11336  42154  84308
7  STI: women  0.40  6720  13440  49920  99840  6720  13440  49920  99840
8  Military  0.20  180  360  1530  3060  7  14  61  122
9  Police  0.20  568  1135  4825  9649  36  72  306  612
10  Health workers  0.20  720  1440  6120  12240  32  65  275  551
11  Pregnant women  0.20  4200  8400  35700  71400  4200  8400  35700  71400
12  HS and univ.students  0.20  11452  22903  97339  194677  3600  7200  30600  61200
13  Conscripts  0.20  960  1920  8160  16320  960  1920  8160  16320
Total: 13  groups  37364  74727  297680  595359  21224  42447  167177  334353
1 Men: 15-49  0.30  59195  118389  469004  938008  2275  4550  18025  36050
2 Women:  15-49  0.30  61042  122084  483640  967279  2275  4550  18025  36050
Total population. 15-49  120237  240473  952644  1905288  4550  9100  36050  72100
Source: See table 12
In this study we considered this vaccine with a 100 percent efficacy and coverage and
life time duration, calculating costs only for one or two doses, those necessary to achieve
these conditions.  This is not realistic at all, when comparing with existing vaccines  and
especially when taking into account the present probability that an AIDS vaccine will be able
to achieve this (Kribs-Zaleta and Velasco-Hernmndez,  2000), but we considered this exercise  a
good starting point for these values represent the minimum cost of these vaccination strategies
to achieve maximum impact.
With lower efficacy and coverage, potential changes in preventive behavior have to be
taken into account, for a sense of false security may eventually contribute to increased risk
behavior, and result in an unfavorable cost-effectiveness  ratio. A large national  study with
highly-active anti-retroviral  therapy (HAART) patients is under way, which will be able to
indicate if these patients have changed their preventive behavior but at this moment there is
no good information available on this subject. To further deepen the analysis, and in order to
arrive at results that take into consideration all necessary elements, computer mathematical
modeling is essential. This was not contemplated in this study, but should be a next step.
Although intuitive, when calculating the cost of each infection prevented through
vaccination, for two "extreme"  potential target groups, sex workers and the total population, it
22is possible to confirm that the cost of preventing an infection is much different, being more
cost-effective  for sex workers,  and this argument is frequently used to recommend focused
vaccination strategies.
Nevertheless,  an economic rationale based only on epidemiological  evidence
frequently underestimates  the real effectiveness obtained when vaccinating these groups with
very low accessibility  and does not take into account the very important political implications
that exist when a potentially beneficial product is denied to the general population. Although
HIV prevalence  in low-risk groups in Brazil is lower than in other countries with mature
AIDS epidemics, it has spread into the general population and there are important differentials
by region,  social status, and specific groups.  Brazil, with a tradition of strong health and
HIV/AIDS policy, would find it very difficult to implement a limited vaccination program.
Public health resources  are already intensively used in AIDS treatment,  and as the
impact of the vaccination programs on reducing these costs would be on a long time frame,
resources  for vaccination would have to be "new money".  Simple calculations with our
numbers reveal that immunization of all adults  15-49 would cost, at the lowest price and two
doses, I $240 million (1/4 of annual public expenditures on AIDS) for catch up, and another I
$45 million for five-year maintenance, totaling I $285 million.  Immunization for all  13 target
groups would cost I $75 million for catch-up and I $210 million for maintenance, for a total of
I $285 million PPP, the same amount.
Of course, this is the most favorable  scenario, in all aspects, and represents an
important but achievable  financial investment for the country,  indicating that a population
immunization policy would be viable from an economic point of view also. If prices are
higher and impact is less favorable opportunity costs considerations,  and comparisons with
other AIDS programs or other health problems, would influence prioritizing.
Although private payment would be possible for a small proportion of the population,
it is very important to maintain this immunization policy a public policy, for in this way
considerable health impacts in this area have been made possible and equity in access has
been guaranteed.  The Brazilian STI/AIDS Program in a document distributed at the AIDS
Conference in Barcelona, July 2002, declared that "if an effective product is successfully
developed, as expected, at prices compatible with the coverage needs for the control of the
epidemic,  the National HIV Vaccine Committee should participate actively  in the debate on
the availability of vaccines for the entire Brazilian population"  (Brazil, Ministry of Health,
STI/AIDS Program, 2002, pg. 29).
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28Annex la. Sources of HIV incidence and prevalence
(population and behavioral data by group)
Group  Data  sources
Men who have  Harrison et al (1999); Kerr-Pontes  and others (1999); Luna (1998)
sex with mien  National STD/AIDS Program.  2000. "Bela Vista & Horizonte: estudos comportamentais  e
(MSM)  epidemiol6gicos  entre homens que fazem sexo com homens", Ministry of Health,
Brasilia.
National  STD/AIDS Program.  2002. "Comportamento  Sexual da Populacao Brasileira e
Percepq6es HIV/Aids",  www.aids.gov.br/final/biblioteca/avalia4/equipe.htm.
Intravenous Drug  National  STD/AIDS Program Home Page (www.aids.gov.br/final/udi.htm):
Users (IDU)  Caiaffa and others (2001).
www.aids.gov.br/final/biblioteca/avalia8/equipe.htm:  "Contribuigao  dos estudos
multicentricos  frente a epidemia de HIV/AIDS  entre UDI no Brasil"
Bastos, F.I. and M. Hacker.  2002. "Uma decada de pesquisas sobre usuarios de drogas
injetaveis e HIV/aids no Rio de Janeiro".
Mesquita, F. et al. 2002.  "AIDS entre usuArios de drogas injetiveis na Regiao Metropolitana
de Santos na decada de noventa".
Commercial sex  National  STD/AIDS Program Home Page (www.aids.gov.br/final/prevencao/p-sexo.htm)
workers  (CSW)  Luppi, C.G. and Campagnoli; personal communication,  2002
Prisoners  National  STD/AIDS Program Home Page (www.aids.gov.br/fmal/prevencao/presidios.htm)
Marins (1997)
Transport  National  STD/AIDS Program Home Page, 2002
workers  (www.aids.gov.br/fmal/prevencao/trabalho.htm)
Lacerda and others (1997)
Armed forces &  National STD/AIDS Program Home Page, 2002
police  (www.aids.gov.br/final/prevencao/armed.htm)
Szwarcwald and Castilho (2000); Szwarcwald and Carvalho (2001)
Pregnant women  National STD/AIDS Program  Home Page (www.aids.gov.br)
Szwarcwald and Castilho (2000); Szwarcwald and Carvalho (2001); Szwarcwald and others
(2001)
Newborns  National  STD/AIDS Program Home Page (www.aids.gov.br)
Szwarcwald and Castilho (2000); Szwarcwald and Carvalho (2001); Szwarcwald and others
(2001)
STD patients  National  STD/AIDS Progran Home Page (www.aids.gov.br)
(Men & Women)  "Comportamento  Sexual da Popula9io Brasileira e Percepq6es HIV/Aids",  2002.
www.aids.gov.br/final/biblioteca/avalia4/equipe.htm
Health workers  National STD/AIDS Program Home Page (www.aids.gov.br)
Szwarcwald and Castilho (2000);  Szwarcwald and Carvalho (2001)
"Comportamento Sexual da Populagao Brasileira e Percepc6es HIV/Aids",  2002.
www.aids.gov.br/final/biblioteca/avalia4/equipe.htm.
High school  &  National STD/AIDS Program Home Page (www.aids.gov.br)
college students  Szwarcwald and Castilho (2000); Szwarcwald  and Carvalho (2001)
Comportamento  Sexual da Popula9ao  Brasileira e Percepq6es HIV/Aids.
www.aids.gov.br/final/biblioteca/avalia4/equipe.htm,  2002
Population  15 - National STD/AIDS Program Home Page (www.aids.gov.br)
49 (Men &  Szwarcwald and Castilho (2000);  Szwarcwald and Carvalho (2001)
Women)  Comportamento  Sexual da Populaclo Brasileira e Percepq6es HIV/Aids. 2002.
www.aids.gov.br/fmallbiblioteca/avalia4/equipe.htm.
Instituto Brasileiro de Geografia e Estatistica - IBGE, Home page (www.ibge.gov.br)
29Annex  lb. Size,  prevalence,  and number of secondary infections  prevented
(by selected  groups, ex  lanations)
Lifetime  Total
secondary  infections
Lifetime secondary  infections  prevented
HIV  infections without  Condom  with condom  without
prevalence  condom  use rate  use  condom
Group  a  b  c  d  e
Sex  0.1300  Customers- 2 cust/day X 20 days/month  Customers:  90%  31.434  312.260
workers  X  12 months X 5 ys = 2,400 +  Regular partner. 20%
1  regular partner= 2,401
IDU  0.1500  Frequency of use = 10 days/month  Steady:  20%  7 890  9.750
Duration of use =  10 ys  Casual  60%
Needle share = 70%
No. new partners/ use = 0.05
(lOX 12X IOX0.7X0.05)=42
Sexual partners:
Steady:  2 in  10 ys.
Casual:  2 year X 10 = 20
Total. 42 +  20 +  2= 64
Prisoners  0.1500  IDU (70% of HIV positive pnsoners)  Steady:  20%  1.575  2.145
Mean prison time = 3 ys.  Casual:  60%
Frequency of  use:  5 days/month
Needle  share = 70%




Casual: 2/year X 3 = 6
Total: 6.3 + I +  6 3 =  13.3
MSM  0.1000  Steady:  I/ 5 ys / 30 ys = 6  Steady  60%  1.540  12.700
Casual: 4/ yearn  30 ys = 120  Casual: 90%
Total:  126
STD patients - 0.0465  Steady:  lAife  Steady.  30%  1.195  2 883
men  Casual: 2/year/ 30 years = 60  Casual:  60%
Total = 61
Transport  0.0130  Steady:  1.4/ life  Steady:  20%  0 116  0.291
workers  Casual: 20/life  Casual:  66%
Total: 21.4
SDT patients - 0 0225  Steady:  1/ life  Steady:  30%  0.056  0 090
women  Casual- 2/ life  Casual:  60%
Total: 3
Miitary  0.0084  2.77  34%  0.024  0.032
Police  0.0084  1.49  34%  0.017  0.021
Health workers  0.0065  30% male & 70% female  35%  0.012  0 015
1.486 X 0 3 = 0.4458
1.221  X 0.7 = 0.8547
Total:  1.30
Pregnant  0.0047  1.22  35%  0.008  0.010
women
HS &  college  0 0013  3.00  48%  0.003  0.005
students
Conscnpts  0.0013  2.77  48%  0.003  0 005
Men  0.0084  1.49  34%  0.017  0.021
15-49
Women  0.0047  1.22  35%  0.008  0.10
15 -49  1
Note: d = E ab (I - c) +  a, e = (ab) +  a. Rationale of the model:  Model used was developed by the Thai group working with the same subject.
It considers that all sexual or intravenous  drug partners would be infected by contact with the index case. So, column b represents the
lifetime secondary  infections  when condom was not used (model  does not take  into account the probability of  transmission per contact,
therefore represents  the maximum infectivity possible). Column c presents the estimates of condom use for each  group. Columns d and e
present the total number of infections that would be prevented with and without  condoms.
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